A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer.
The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected.
The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.
see:Arms and Interventions
Inclusion Criteria:
Patients volunteered to participate in this study and signed informed consent;
Each center can be enrolled in patients who meet the age of their own practice range, regardless of gender ;
Histologically diagnosed locally advanced or recurrent / metastatic thyroid cancer that cannot undergo radical surgery meets one of the following requirements:
Thyroid-related pathogenic or therapeutic target gene detection was performed before enrollment.
Exclusion Criteria:
jidongmei2000@hotmail.com021-64175590 ext. 83650
Fuzhou, Fujian, China
headandneck2018@126.com13705003480
Wuhan, Hubei, China
qinjianwu62@163.com13598802366
caowei@hust.edu.cn13995658573
lcxzhg1974@163.com18847189559
jidongmei2000@126.com+8602164175590 ext. 73546
jialz2008@163.com15035162908
fangmy@zjcc.org.cn13750851650
linyansong1968@163.com(010)69156699